Company news
Gt Biopharma, Inc. (NASDAQ:GTBP) news
Gt Biopharma, Inc. news releases on 6ix. Latest, Sep 22, 2020: GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update
Press releases — page 3
GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update
September 21, 2020
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
August 19, 2020
GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
August 3, 2020
GT Biopharma Announces Completion of $5.6 Million Bridge Financing
July 21, 2020
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
May 26, 2020
GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
March 30, 2020
GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia
March 18, 2020
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection
March 9, 2020
GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
February 25, 2020
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives
January 20, 2020
GT Biopharma Announces Solid Tumor Targeting TriKe(TM) Kills
October 21, 2019